Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0000950170-25-057537
Filing Date
2025-04-23
Accepted
2025-04-23 17:26:31
Documents
2

Document Format Files

Seq Description Document Type Size
1 DEFA14A vktx-2025-04-23-defa14a_.htm DEFA14A 12303
2 GRAPHIC img30215864_0.jpg GRAPHIC 368438
  Complete submission text file 0000950170-25-057537.txt   520962
Mailing Address 9920 PACIFIC HEIGHTS BLVD, SUITE 350 SAN DIEGO CA 92121
Business Address 9920 PACIFIC HEIGHTS BLVD, SUITE 350 SAN DIEGO CA 92121 858-704-4660
Viking Therapeutics, Inc. (Filer) CIK: 0001607678 (see all company filings)

EIN.: 461073877 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-37355 | Film No.: 25862795
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)